Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial

• Hoofdauteurs: Maria G. Fencer MD (Auteur), Catherine H. Davis MD, MPH (Auteur), Jieqi Liu MD (Auteur), Mark A. Galan MD (Auteur), Kristen R. Spencer DO, MPH (Auteur)
• Formaat: Boek
• Gepubliceerd in: SAGE Publishing, 2022-12-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Here...